Perceptive’s investment strategies are built upon extensive fundamental analysis and decades of experience investing in small and mid-capitalization healthcare companies. Our approach is based on an in depth scientific analysis of every step in the development pathway of a new therapeutic, device, or diagnostic. We seek to avoid the biases that can affect investment decisions and have the ability to adapt to meet an evolving landscape.
Perceptive seeks to invest in private companies that offer innovative solutions to healthcare needs. Below is a list of our partners:
Acerta Pharma BV is a Biotech company that combines two technology platforms in drug discovery and development: the Covalent Technology Platform and the Multiparametric Phosphoflow Cytometry Platform. These platforms ensure rapid identification and optimization of high-quality drug candidates and enable administering the right drug to the right patient at the right dose.
A clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. The company engineers and develops next-generation bispecific antibodies that bind with high specificity and affinity to certain cancer cells and direct the most potent cells of the human immune defense arsenal, to attack and kill cancer cells.
Alliqua Biomedical is a leading provider of advanced wound care solutions. The company is building a portfolio through targeted acquisitions and through licensing and distribution agreements with their strategic partner Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation.
Bellicum's CID Technology Enhances Potential of Cellular Immunotherapy Cell signaling switches enable control over immune activity. Bellicum’s unique technology, designed to give physicians control over cells and immune activity inside the body, aims to make cell therapies safer and more effective.
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
A clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs.
GenSight is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
Global Blood Therapeutics (GBT)
Global Blood Therapeutics (GBT) is a clinical stage biopharmaceutical company developing novel small molecule therapeutics to treat grievous, non-malignant blood-based conditions for which there are currently only limited therapy.
Kadmon is a biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Founded in 2009, Kadmon has pioneered a new approach to the traditional biotechnology model by building, from inception, a vertically integrated company comprising innovative drug discovery platforms, a deep clinical pipeline and a commercial operation with specialty pharmaceutical products.
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
MeiraGTx develops innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. We are pioneering the use of gene therapy to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). MeiraGTx is developing novel gene regulation platforms that promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
Oncobiologics is a complex biosimilar company focused on developing technically challenging biosimilars in a cost effective way. The first wave of Phase 3 ready products include ONS-3010 (Humira® Biosimilar) and ONS-1045 (Avastin® Biosimilar).
Otonomy’s mission is to develop and commercialize novel and best-in-class therapeutics to address unmet medical needs in the emerging otology market, which overcome many of the limitations of delivering drugs to the middle and inner ear.
Outset Medical is focused on reimagining the experience of dialysis care for patients with kidney disease by providing them greater flexibility, independence, and control with the potential to dramatically lower cost for providers and the healthcare system.
A biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are currently limited patient options.
Solid GT is a gene therapy platform for advancing disease modifying therapies for Duchenne muscular dystrophy.
A private company focused on acquiring and developing disease modifying therapies for Duchenne Muscular Dystrophy through rigorous scientific analysis, efficient capital management and global collaborations.
Tivorsan Pharmaceuticals is a protein therapeutics company pioneering a unique approach to treat serious neuromuscular disorders, including Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
True North Therapeutics
True North is guided by the needs of patients as we discover life-changing medicines for rare diseases. We combine scientific and clinical expertise in diseases of the Complement system so that we can rapidly develop new drugs for rare diseases with few, if any, treatment options. Our R&D is focused on finding novel drugs for rare diseases in which complement is a key driver of pathogenesis. We concentrate on therapies that can intervene upstream in the Complement system, selectively targeting the pathway underlying the disease.
Vapotherm is dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery cost and improve quality of life for patients. Vapotherm High Flow Therapy provides support for patients in respiratory distress and has been used in over half a million patients.
A biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. The vaccine platform allows for the design of vaccines that closely mimic the target virus. VBI has also completed proof of concept thermostability studies on a number of vaccine and biologic
A biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders utilizing the novel half-life extension technology, XTEN, in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD).
Vyome Biosciences is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development.
Zenefits is a cloud based healthcare insurance broker focused on gaining market share by providing small businesses with HR software for free.
Zymeworks is committed to the development of best in class antibody and protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.
Zynerba Pharmaceuticals is dedicated to the development of next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery for patients with significant medical need. Their mission is to improve the lives of patients battling severe health conditions including peripheral neuropathic pain, fibromyalgia,chronic cancer pain, refractory epilepsy and osteoarthritis through synthetic cannabinoid therapeutics formulated for transdermal delivery.